74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Quanterix Corp
Open
SectorHealthcare
6.2 -8.15
Overview
Share price change
24h
Min
6.14
Max
6.74
Income | -4.3M -12M |
|---|---|
Sales | -249K 35M |
EPS | -0.3 |
Profit margin | -33.07 |
Employees | 471 |
EBITDA | -3.8M -15M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +117.72% upside |
Next Earnings | 6 May 2025 |
|---|
Market Cap | -107M 254M |
|---|---|
Previous open | 14.35 |
Previous close | 6.2 |
News Sentiment
By Acuity
92%
8%
371 / 386 Healthcare
Technical Score
By Trading Central
Confidence
Bearish Evidence
Quanterix Corp Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Quanterix Corp Forecast
Price Target
By TipRanks
117.72% upside
12 Months Forecast
Average 14.5 USD 117.72%
High 18 USD
Low 10 USD
Based on 4 Wall Street analysts offering 12 month price targets forQuanterix Corp - Dist in the last 3 months.
Sentiment
By Acuity
371 / 386 Healthcare
News Sentiment
Very Strong Bearish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Quanterix Corp
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
